GlassScriptPhysician profile
Ruben Cabral
NPI 1568458008
$2,120.04
in general payments reported to CMS, 2019-2025
17 companies · $48.58 in 2025
The $48.58 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,200 · 2020: $339 · 2021: $210 · 2022: $78.16 · 2023: $209 · 2024: $36.24 · 2025: $48.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232 · Education: $61.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $231.91 |
| Education | $61.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $437.07 | 2019-2023 | Myrbetriq |
| Amgen INC. | $360.49 | 2019-2021 | |
| Pfizer INC. | $240.87 | 2019-2021 | |
| Novo Nordisk INC | $239.94 | 2019-2025 | Ozempic, Rybelsus |
| Allergan, INC. | $213.41 | 2019-2020 | |
| Lilly USA, LLC | $176.69 | 2019-2020 | |
| Glaxosmithkline, LLC. | $149.24 | 2019-2023 | Trelegy Ellipta, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $100.15 | 2021-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $42.19 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.37 | 2020-2024 | Jardiance |
| Dynavax Technologies Corporation | $22.60 | 2019 | |
| Abbvie INC. | $20.27 | 2022 | |
| Sanofi Pasteur INC. | $19.76 | 2019 | |
| Cmp Pharma, INC. | $15.75 | 2023 | Norliqva |
| Vertiflex, INC. | $15.31 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Assertio Therapeutics, INC. | $14.67 | 2019 | |
| Horizon Therapeutics Plc | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruben Cabral listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.